JP2015534817A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534817A5 JP2015534817A5 JP2015540833A JP2015540833A JP2015534817A5 JP 2015534817 A5 JP2015534817 A5 JP 2015534817A5 JP 2015540833 A JP2015540833 A JP 2015540833A JP 2015540833 A JP2015540833 A JP 2015540833A JP 2015534817 A5 JP2015534817 A5 JP 2015534817A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- protein
- gene editing
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018073676A JP6890565B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721302P | 2012-11-01 | 2012-11-01 | |
| US61/721,302 | 2012-11-01 | ||
| US201361785404P | 2013-03-14 | 2013-03-14 | |
| US61/785,404 | 2013-03-14 | ||
| US201361842874P | 2013-07-03 | 2013-07-03 | |
| US61/842,874 | 2013-07-03 | ||
| PCT/US2013/068118 WO2014071219A1 (en) | 2012-11-01 | 2013-11-01 | Methods and products for expressing proteins in cells |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018073676A Division JP6890565B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2018073677A Division JP6793146B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015534817A JP2015534817A (ja) | 2015-12-07 |
| JP2015534817A5 true JP2015534817A5 (OSRAM) | 2016-12-15 |
| JP6510416B2 JP6510416B2 (ja) | 2019-05-08 |
Family
ID=50628111
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540833A Active JP6510416B2 (ja) | 2012-11-01 | 2013-11-01 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2018073677A Active JP6793146B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2018073676A Active JP6890565B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2021027831A Active JP7436406B2 (ja) | 2012-11-01 | 2021-02-24 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2024018042A Pending JP2024056815A (ja) | 2012-11-01 | 2024-02-08 | 細胞中でタンパク質を発現するための方法および生成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018073677A Active JP6793146B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2018073676A Active JP6890565B2 (ja) | 2012-11-01 | 2018-04-06 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2021027831A Active JP7436406B2 (ja) | 2012-11-01 | 2021-02-24 | 細胞中でタンパク質を発現するための方法および生成物 |
| JP2024018042A Pending JP2024056815A (ja) | 2012-11-01 | 2024-02-08 | 細胞中でタンパク質を発現するための方法および生成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (19) | US9447395B2 (OSRAM) |
| EP (2) | EP2914728B1 (OSRAM) |
| JP (5) | JP6510416B2 (OSRAM) |
| KR (4) | KR102315098B1 (OSRAM) |
| CN (1) | CN104769112A (OSRAM) |
| AU (3) | AU2013337651B2 (OSRAM) |
| BR (2) | BR122019025681B1 (OSRAM) |
| CA (2) | CA3150985A1 (OSRAM) |
| MX (2) | MX363017B (OSRAM) |
| RU (2) | RU2019143431A (OSRAM) |
| WO (1) | WO2014071219A1 (OSRAM) |
Families Citing this family (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RS63430B1 (sr) | 2010-10-01 | 2022-08-31 | Modernatx Inc | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| PT3892295T (pt) | 2011-05-24 | 2023-06-01 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacinas individualizadas para o cancro |
| EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK3682905T3 (da) | 2011-10-03 | 2022-02-28 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf |
| DE12858350T1 (de) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
| JP2015529685A (ja) | 2012-09-17 | 2015-10-08 | ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルＴｈｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ａｔｎａｔｉｏｎｗｉｄｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ | 筋萎縮性側索硬化症の処置のための組成物および方法 |
| KR102315098B1 (ko) | 2012-11-01 | 2021-10-21 | 팩터 바이오사이언스 인크. | 세포에서 단백질을 발현시키는 방법들과 생성물들 |
| HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| EP4483965A3 (en) | 2012-11-28 | 2025-04-02 | BioNTech SE | Individualized vaccines for cancer |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| US10704060B2 (en) * | 2013-06-05 | 2020-07-07 | Duke University | RNA-guided gene editing and gene regulation |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| PT3039146T (pt) | 2013-08-27 | 2020-08-11 | The Res Institute At Nationwide Childrens Hospital | Produtos e métodos para tratamento de esclerose lateral amiotrófica |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| AU2014346987A1 (en) | 2013-11-05 | 2016-06-23 | The Research Institute At Nationwide Children's Hospital | Compositions and methods for inhibiting NF-kB and SOD-1 to treat amyotrophic lateral sclerosis |
| CN111218447B (zh) | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| WO2015138739A2 (en) * | 2014-03-12 | 2015-09-17 | Precision Biosciences, Inc. | Dystrophin gene oxon deletion using engineered nucleases |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| EP3140403A4 (en) * | 2014-05-09 | 2017-12-20 | Université Laval | Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| CN113016623A (zh) | 2014-09-26 | 2021-06-25 | 谱赛科美国股份有限公司 | 用于甜菊的单核苷酸多态性(snp)标志物 |
| RU2716422C2 (ru) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | Композиции и способы лечения бокового амиотрофического склероза (als) |
| EP3223846B1 (en) * | 2014-11-26 | 2023-09-06 | Huvepharma, Inc. | Adjuvant compositions and related methods |
| US10195261B2 (en) | 2014-11-26 | 2019-02-05 | VaxLiant, LLC | Adjuvant compositions and related methods |
| AU2015355546B2 (en) | 2014-12-03 | 2021-10-14 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
| WO2016130600A2 (en) | 2015-02-09 | 2016-08-18 | Duke University | Compositions and methods for epigenome editing |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| CA2976376A1 (en) | 2015-02-13 | 2016-08-18 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| JP6925277B2 (ja) | 2015-03-24 | 2021-08-25 | ヒューベファーマ・インコーポレイテッドＨｕｖｅｐｈａｒｍａ， Ｉｎｃ． | アジュバント組成物及び関連する方法 |
| WO2016164356A1 (en) | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
| ES3009026T3 (en) | 2015-07-22 | 2025-03-25 | Univ Duke | High-throughput screening of regulatory element function with epigenome editing technologies |
| EP3325622B1 (en) * | 2015-07-25 | 2023-06-07 | Frost, Habib | A system, device and a method for providing a therapy or a cure for cancer and other pathological states |
| EA201890565A1 (ru) | 2015-08-25 | 2019-04-30 | Дьюк Юниверсити | Композиции и способы улучшения специфичности в геномной инженерии с применением рнк-направляемых эндонуклеаз |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| WO2017066497A2 (en) | 2015-10-13 | 2017-04-20 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
| DK3362461T3 (da) | 2015-10-16 | 2022-05-09 | Modernatx Inc | Mrna-cap-analoger med modificeret phosphatbinding |
| US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
| US11459560B2 (en) * | 2015-11-23 | 2022-10-04 | The Regents Of The University Of Colorado | Methods and compositions for reprogramming cells |
| EP3384055B1 (en) | 2015-11-30 | 2025-07-16 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
| CN105494263B (zh) * | 2015-12-25 | 2018-11-30 | 哈尔滨医科大学 | 一种产生ho-1/app/psen1三转基因阿尔茨海默病小鼠模型的方法 |
| EP3411078A1 (en) * | 2016-02-02 | 2018-12-12 | Crispr Therapeutics AG | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
| WO2017141109A1 (en) * | 2016-02-18 | 2017-08-24 | Crispr Therapeutics Ag | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
| WO2017147278A1 (en) | 2016-02-25 | 2017-08-31 | The Children's Medical Center Corporation | Customized class switch of immunoglobulin genes in lymphoma and hybridoma by crispr/cas9 technology |
| EP3429632B1 (en) | 2016-03-16 | 2023-01-04 | CRISPR Therapeutics AG | Materials and methods for treatment of hereditary haemochromatosis |
| WO2017167910A1 (en) * | 2016-03-31 | 2017-10-05 | Ethris Gmbh | Novel minimal utr sequences |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| WO2017181107A2 (en) * | 2016-04-16 | 2017-10-19 | Ohio State Innovation Foundation | Modified cpf1 mrna, modified guide rna, and uses thereof |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| EP4219462A1 (en) * | 2016-07-13 | 2023-08-02 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
| EP3487523B1 (en) | 2016-07-19 | 2023-09-06 | Duke University | Therapeutic applications of cpf1-based genome editing |
| GB2568182A (en) | 2016-08-03 | 2019-05-08 | Harvard College | Adenosine nucleobase editors and uses thereof |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| AU2017312113B2 (en) | 2016-08-17 | 2023-05-25 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| CN106370765A (zh) * | 2016-08-23 | 2017-02-01 | 国家烟草质量监督检验中心 | 一种基于反相色谱飞行时间质谱的喉癌尿液差异代谢物的测定筛选方法 |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| CN106381310B (zh) * | 2016-08-31 | 2020-02-04 | 武汉华美生物工程有限公司 | 一种用t7噬菌体rna聚合酶和t7启动子系统在哺乳动物细胞表达蛋白的方法 |
| GB2573062A (en) | 2016-10-14 | 2019-10-23 | Harvard College | AAV delivery of nucleobase editors |
| JP2020500218A (ja) * | 2016-11-11 | 2020-01-09 | ディーエヌエーライト セラピューティクス， インコーポレイテッド | 遺伝子治療のための構造体および方法 |
| KR101908593B1 (ko) * | 2016-12-07 | 2018-10-16 | 연세대학교 산학협력단 | Cftr 유전자 소실 유도 가이드 rna, cftr 변이를 갖는 t84 세포 및 이의 용도 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| EP3585807A1 (en) * | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
| US11168319B1 (en) * | 2017-02-28 | 2021-11-09 | Inari Agriculture Technology, Inc. | Plant cell culture |
| EP3589290A4 (en) * | 2017-02-28 | 2020-12-30 | Arcturus Therapeutics, Inc. | Translatable molecules and synthesis thereof |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| WO2018165631A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Cancer vaccine |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| CN107475255B (zh) * | 2017-03-21 | 2021-03-26 | 河北医科大学第二医院 | 一种基因载体介导的基于CRISPR/Cas9基因编辑系统的sgRNA及其用途 |
| US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法 |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| US11002729B2 (en) * | 2017-06-14 | 2021-05-11 | Wuhan Institute Of Virology, Chinese Academy Of Sciences | CD2-associated protein (CD2AP) and its interactive proteins |
| JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物 |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| CN119242711A (zh) | 2017-10-16 | 2025-01-03 | 沃雅戈治疗公司 | 肌萎缩性侧索硬化症（als）的治疗 |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| EP3728577A4 (en) | 2018-01-22 | 2021-12-22 | Inari Agriculture, Inc. | PLANT GENE EDITING SYSTEMS, METHODS AND COMPOSITIONS |
| AU2019243155A1 (en) * | 2018-03-27 | 2020-10-15 | Factor Bioscience Inc. | Nucleic acid-based therapeutics |
| JP2021523733A (ja) | 2018-04-18 | 2021-09-09 | アルティウス インスティテュート フォー バイオメディカル サイエンスィズ | 動物病原体由来ポリペプチドおよびその遺伝子工学的利用 |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| CN108624592B (zh) * | 2018-05-24 | 2021-08-17 | 苏州大学张家港工业技术研究院 | 针对DJ-1基因编辑的sgRNA筛选及其载体与应用 |
| US12264181B2 (en) | 2018-06-27 | 2025-04-01 | Altius Institute For Biomedical Sciences | Nucleic acid binding domains and methods of use thereof |
| AU2019293244A1 (en) * | 2018-06-27 | 2021-02-11 | Modernatx, Inc. | Personalized cancer vaccine epitope selection |
| CN108949830B (zh) * | 2018-08-03 | 2021-11-26 | 福州大学 | 一种在鱼类中实现基因组编辑、精确定点基因敲入的方法 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| CN109628404B (zh) * | 2018-12-18 | 2020-04-28 | 浙江大学 | 猪皮下脂肪前体细胞永生化细胞系的构建方法及用途 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| AU2020240109A1 (en) | 2019-03-19 | 2021-09-30 | President And Fellows Of Harvard College | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN110200973A (zh) * | 2019-06-19 | 2019-09-06 | 南京市儿童医院 | Dna依赖性蛋白激酶特异性抑制剂在制备防治肾纤维化药物中的用途 |
| EP3997059A4 (en) | 2019-07-03 | 2023-12-13 | Factor Bioscience Inc. | CATIONIC LIPIDS AND THEIR USES |
| WO2021016043A1 (en) | 2019-07-19 | 2021-01-28 | Inari Agriculture, Inc. | Improved homology dependent repair genome editing |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| CN110699381A (zh) * | 2019-09-17 | 2020-01-17 | 合肥瑞灵生物科技有限公司 | 地中海贫血病基因治疗载体构建方法及其用途 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| WO2021191678A1 (en) | 2020-03-23 | 2021-09-30 | Avectas Limited | Engineering of dendritic cells for generation of vaccines against sars-cov-2 |
| BR112022022603A2 (pt) | 2020-05-08 | 2023-01-17 | Broad Inst Inc | Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla |
| CN113151181B (zh) * | 2021-04-14 | 2022-11-29 | 中山大学附属第七医院(深圳) | 一种脂肪干细胞重编程为神经元的方法及负载该神经元的细胞适应性水凝胶修复脊髓损伤 |
| CN113373214B (zh) * | 2021-06-18 | 2024-03-29 | 中国人民解放军军事科学院军事医学研究院 | Cd30在诊断脑神经相关疾病中的用途 |
| WO2023039586A1 (en) | 2021-09-10 | 2023-03-16 | Agilent Technologies, Inc. | Guide rnas with chemical modification for prime editing |
| CN114150017B (zh) * | 2021-11-30 | 2023-05-16 | 长江大学 | 一种调节猪未成熟睾丸支持细胞乳酸分泌水平的方法及应用 |
| CN119731321A (zh) | 2022-06-24 | 2025-03-28 | 图恩疗法股份有限公司 | 通过靶向基因阻遏减少低密度脂蛋白的组合物、系统和方法 |
| WO2024032678A1 (zh) * | 2022-08-11 | 2024-02-15 | 益杰立科(上海)生物科技有限公司 | 一种表观编辑靶点的方法及用途 |
| WO2025084896A1 (ko) * | 2023-10-18 | 2025-04-24 | 연세대학교 산학협력단 | 신경세포 분화 유도용 재조합 벡터 및 이를 포함하는 퇴행성 뇌신경 질환의 예방 또는 치료용 약학적 조성물 |
| CN118667815B (zh) * | 2024-07-16 | 2025-02-14 | 宁夏大学 | 一种靶向prdm1改善牛子宫内膜炎的核苷酸序列及其应用 |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539465A (en) | 1968-10-08 | 1970-11-10 | Ncr Co | Encapsulation of hydrophilic liquid-in-oil emulsions |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US6743771B2 (en) * | 1995-12-29 | 2004-06-01 | Novactyl, Inc. | Methods and compositions for controlling protein assembly or aggregation |
| JP2001508302A (ja) | 1997-01-10 | 2001-06-26 | ライフ テクノロジーズ，インコーポレイテッド | 胚性幹細胞血清置換 |
| CA2304982A1 (en) | 1997-09-19 | 1999-03-25 | Sequitur, Inc. | Sense mrna therapy |
| US20110171185A1 (en) | 1999-06-30 | 2011-07-14 | Klimanskaya Irina V | Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof |
| US7621606B2 (en) | 2001-08-27 | 2009-11-24 | Advanced Cell Technology, Inc. | Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
| CA2423487C (en) | 2000-09-26 | 2015-12-15 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| US20050130144A1 (en) | 2001-09-21 | 2005-06-16 | Norio Nakatsuji | Method of screening reprogramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs |
| WO2003033697A1 (en) | 2001-10-18 | 2003-04-24 | Ixion Biotechnology, Inc. | Conversion of liver stem and progenitor cells to pancreatic functional cells |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| GB0202149D0 (en) | 2002-01-30 | 2002-03-20 | Univ Edinburgh | Pluripotency determining factors and uses thereof |
| AU2004253455B2 (en) | 2003-06-03 | 2011-03-03 | Eli Lilly And Company | Modulation of survivin expression |
| US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
| GB2432835B (en) | 2004-09-08 | 2009-04-08 | Wisconsin Alumni Res Found | Culturing human embryonic stem cells |
| WO2006029197A1 (en) | 2004-09-08 | 2006-03-16 | Wisconsin Alumni Research Foundation | Medium and culture of embryonic stem cells |
| MX2007008982A (es) * | 2005-01-25 | 2007-12-06 | Cell Therapeutics Inc | Conjugados de proteinas biologicamente activas que tienen una vida media modificada in vivo. |
| EP1904528B1 (en) * | 2005-07-13 | 2012-10-31 | Novo Nordisk Health Care AG | Host cell protein knock-out cells for production of therapeutic proteins |
| KR101419729B1 (ko) * | 2005-07-26 | 2014-07-17 | 상가모 바이오사이언스 인코포레이티드 | 외래 핵산 서열의 표적화된 통합 및 발현 |
| US20090263900A1 (en) * | 2008-04-14 | 2009-10-22 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
| US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| EP4174179B1 (en) | 2005-08-23 | 2025-05-07 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| US8476070B2 (en) | 2005-08-29 | 2013-07-02 | Technion Research & Development Foundation Limited | Media for culturing stem cells |
| ZA200804673B (en) | 2005-12-13 | 2009-11-25 | Univ Kyoto | Nuclear reprogramming factor |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| AU2006334795B2 (en) | 2005-12-22 | 2012-02-16 | Csl Behring Gmbh | Octanoate-reduced human albumin |
| DE102006051516A1 (de) * | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
| GB0623635D0 (en) | 2006-11-27 | 2007-01-03 | Stem Cell Sciences Uk Ltd | Pluripotent cell growth media |
| US20080213377A1 (en) | 2006-12-08 | 2008-09-04 | Bhatia Sangeeta N | Delivery of Nanoparticles and/or Agents to Cells |
| US10829733B2 (en) | 2007-01-04 | 2020-11-10 | Biolamina Ab | Composition and method for enabling proliferation of pluripotent human stem cells |
| WO2008086529A2 (en) | 2007-01-11 | 2008-07-17 | Yale University | Compositions and methods for targeted inactivation of hiv cell surface receptors |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| WO2008097926A2 (en) | 2007-02-02 | 2008-08-14 | Yale University | Transient transfection with rna |
| WO2008118820A2 (en) | 2007-03-23 | 2008-10-02 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
| CA2683056C (en) | 2007-04-07 | 2020-03-24 | Whitehead Institute For Biomedical Research | Reprogramming of somatic cells |
| KR101532442B1 (ko) | 2007-12-10 | 2015-06-29 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 효율적인 핵 초기화 방법 |
| EP2072618A1 (en) | 2007-12-14 | 2009-06-24 | Johannes Gutenberg-Universität Mainz | Use of RNA for reprogramming somatic cells |
| SG188904A1 (en) | 2008-03-17 | 2013-04-30 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| US20110045001A1 (en) | 2008-03-28 | 2011-02-24 | Biontex Laboratories Gmbh | Transfection results of non-viral gene delivery systems by influencing of the innate immune system |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| EP3279314A1 (en) | 2008-06-04 | 2018-02-07 | Cellular Dynamics International, Inc. | Methods for the production of ips cells using non-viral approach |
| GB2460552B (en) | 2008-06-05 | 2011-09-07 | Iti Scotland Ltd | Stem cell culture media and methods |
| WO2010008486A2 (en) | 2008-06-24 | 2010-01-21 | Parkinsons Institute | Pluripotent cell lines and methods of use thereof |
| US20100184033A1 (en) | 2008-07-16 | 2010-07-22 | West Michael D | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
| EP2326711A2 (en) | 2008-08-20 | 2011-06-01 | VIRxSYS Corporation | Compositions and methods for generation of pluripotent stem cells |
| CA2741090C (en) | 2008-10-24 | 2018-10-16 | Wisconsin Alumni Research Foundation | Pluripotent stem cells obtained by non-viral reprogramming |
| EP2192174B1 (en) | 2008-11-21 | 2015-11-11 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Reprogramming cells toward a pluripotent state |
| US20110023141A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved with parkinson's disease |
| WO2010079340A2 (en) | 2009-01-08 | 2010-07-15 | Eisai R & D Management Co., Ltd. | Assay |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| EP2213990B1 (fr) | 2009-01-22 | 2016-08-17 | Johnson Controls Technology Company | Procédé de calibration et/ou de correction d'un dispositif d'affichage ayant une aiguille, l'aiguille étant mobile en rotation autour d'un axe de rotation |
| US20100209404A1 (en) | 2009-02-10 | 2010-08-19 | University Of Dayton | Enhanced method for producing stem-like cells from somatic cells |
| US10894944B2 (en) | 2009-04-10 | 2021-01-19 | Monash University | Cell culture media |
| WO2010123501A1 (en) | 2009-04-22 | 2010-10-28 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
| US20100272695A1 (en) | 2009-04-22 | 2010-10-28 | Alan Agulnick | Cell compositions derived from dedifferentiated reprogrammed cells |
| US10837020B2 (en) | 2009-04-22 | 2020-11-17 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long RNA molecules |
| US8496941B2 (en) | 2009-06-03 | 2013-07-30 | National Institute Of Advanced Industrial Science And Technology | Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same |
| EP3581197A1 (de) | 2009-07-31 | 2019-12-18 | ethris GmbH | Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression |
| US8802437B2 (en) * | 2009-09-24 | 2014-08-12 | Cellectis | Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations |
| WO2011050470A1 (en) * | 2009-10-29 | 2011-05-05 | Mcmaster University | Generating induced pluripotent stem cells and progenitor cells from fibroblasts |
| WO2011056971A2 (en) | 2009-11-04 | 2011-05-12 | Cellular Dynamics International, Inc. | Episomal reprogramming with chemicals |
| WO2011060100A1 (en) | 2009-11-11 | 2011-05-19 | Sanford-Burnham Medical Research Institute | Method for generation and regulation of ips cells and compositions thereof |
| LT3287525T (lt) | 2009-12-07 | 2020-02-10 | The Trustees Of The University Of Pennsylvania | Rnr preparatai, apimantys išgrynintą modifikuotą rnr, skirti ląstelių reprogramavimui |
| US20130189741A1 (en) | 2009-12-07 | 2013-07-25 | Cellscript, Inc. | Compositions and methods for reprogramming mammalian cells |
| CN106834320B (zh) | 2009-12-10 | 2021-05-25 | 明尼苏达大学董事会 | Tal效应子介导的dna修饰 |
| US8557972B2 (en) | 2009-12-21 | 2013-10-15 | University Of Washington Through Its Center For Commercialization | Compositions and methods for transfection of RNA and controlled stabilization of transfected RNA |
| CA2788635A1 (en) * | 2010-02-01 | 2011-08-04 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced efficiency of induced pluripotent stem cell generation |
| WO2011110886A1 (en) | 2010-03-09 | 2011-09-15 | Biolamina Ab | Composition and method for enabling proliferation of pluripotent human stem cells |
| CA3122219A1 (en) | 2010-04-16 | 2011-10-20 | The Children's Hospital Corporation | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| WO2011140397A2 (en) | 2010-05-05 | 2011-11-10 | The Regents Of The University Of California Office Of The President | Stem cell defined media for xeno-free and feeder free conditions and uses thereof |
| US8048675B1 (en) | 2010-05-12 | 2011-11-01 | Ipierian, Inc. | Integration-free human induced pluripotent stem cells from blood |
| WO2011141820A1 (en) * | 2010-05-12 | 2011-11-17 | Cellectis | Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof |
| JP6208580B2 (ja) * | 2010-05-17 | 2017-10-04 | サンガモ セラピューティクス， インコーポレイテッド | 新規のｄｎａ結合タンパク質及びその使用 |
| EP2392208B1 (en) * | 2010-06-07 | 2016-05-04 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use |
| EP2580331A4 (en) * | 2010-06-14 | 2013-11-27 | Univ Iowa State Res Found Inc | NUCLEASE ACTIVITY OF THE TAL EFFECTOR AND FUSION PROTEIN FOKI |
| CA2802249A1 (en) * | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
| AU2011285531B2 (en) | 2010-08-05 | 2015-04-30 | Wisconsin Alumni Research Foundation | Simplified basic media for human pluripotent cell culture |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US20140127814A1 (en) | 2010-08-10 | 2014-05-08 | Srinivasan Chandrasegaran | Generation and use of pluripotent stem cells |
| GB201014169D0 (en) * | 2010-08-25 | 2010-10-06 | Cambridge Entpr Ltd | In vitro hepatic differentiation |
| EP2616540A4 (en) | 2010-09-14 | 2014-02-19 | Univ Kyoto | METHOD FOR EFFICIENT MANUFACTURE OF INDUCED PLURIPOTENTER STEM CELLS |
| EP2622090B1 (en) * | 2010-09-27 | 2019-06-19 | Sangamo Therapeutics, Inc. | Compositions for inhibiting viral entry into cells |
| RS63430B1 (sr) | 2010-10-01 | 2022-08-31 | Modernatx Inc | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene |
| US20130273656A1 (en) * | 2010-10-08 | 2013-10-17 | Regents Of The University Of Minnesota | Method to increase gene targeting frequency |
| US9637732B2 (en) | 2010-11-04 | 2017-05-02 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| WO2012094132A1 (en) * | 2011-01-05 | 2012-07-12 | Sangamo Biosciences, Inc. | Methods and compositions for gene correction |
| US9499592B2 (en) | 2011-01-26 | 2016-11-22 | President And Fellows Of Harvard College | Transcription activator-like effectors |
| KR20120096395A (ko) * | 2011-02-22 | 2012-08-30 | 주식회사 툴젠 | 뉴클레아제에 의해 유전자 변형된 세포를 농축시키는 방법 |
| WO2012116274A2 (en) * | 2011-02-25 | 2012-08-30 | Recombinetics, Inc. | Genetically modified animals and methods for making the same |
| AU2012225497A1 (en) * | 2011-03-07 | 2013-10-24 | Massachusetts Institute Of Technology | Methods for transfecting cells with nucleic acids |
| EP2691101A2 (en) * | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| JP2014511694A (ja) * | 2011-04-03 | 2014-05-19 | ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル | 修飾型ｒｎａ（ｍｏｄ−ｒｎａ）を使用する効率的なインビボタンパク質発現 |
| CA3111953C (en) * | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| US9862926B2 (en) | 2011-06-27 | 2018-01-09 | Cellscript, Llc. | Inhibition of innate immune response |
| JP2014520551A (ja) | 2011-07-11 | 2014-08-25 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 細胞のリプログラミング方法およびゲノムの改変方法 |
| CA2848417C (en) * | 2011-09-21 | 2023-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
| DK3682905T3 (da) | 2011-10-03 | 2022-02-28 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf |
| CN111893140A (zh) * | 2011-12-05 | 2020-11-06 | 菲克特生物科学股份有限公司 | 用于转染细胞的方法和产品 |
| US8497124B2 (en) | 2011-12-05 | 2013-07-30 | Factor Bioscience Inc. | Methods and products for reprogramming cells to a less differentiated state |
| DE12858350T1 (de) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
| WO2013096709A2 (en) | 2011-12-21 | 2013-06-27 | modeRNA Therapeutics | Methods of increasing the viability or longevity of an organ or organ explant |
| HUE047947T2 (hu) | 2011-12-30 | 2020-05-28 | Cellscript Llc | In vitro szintetizált ssRNS elõállítása és alkalmazása emlõssejtekbe történõ bevezetésre biológiai vagy biokémiai hatás indukálására |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| WO2013152220A2 (en) * | 2012-04-04 | 2013-10-10 | Life Technologies Corporation | Tal-effector assembly platform, customized services, kits and assays |
| CA2870288A1 (en) | 2012-04-10 | 2013-10-17 | John J. Rossi | Rna aptamers for therapeutic and diagnostic delivery to pancreatic cancer cells |
| US11963977B2 (en) | 2012-04-24 | 2024-04-23 | Vcell Therapeutics Inc. | Generating pluripotent cells de novo |
| US9738879B2 (en) * | 2012-04-27 | 2017-08-22 | Duke University | Genetic correction of mutated genes |
| US10155929B2 (en) | 2012-05-13 | 2018-12-18 | Allele Biotechnology & Pharmaceuticals, Inc. | Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA |
| US10119150B2 (en) | 2012-05-13 | 2018-11-06 | Allele Biotechnology & Pharmaceuticals, Inc. | Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA |
| CA2872688C (en) | 2012-05-13 | 2023-09-19 | Allele Biotechnology And Pharmaceuticals, Inc. | Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna |
| ES2613691T3 (es) * | 2012-07-11 | 2017-05-25 | Sangamo Biosciences, Inc. | Métodos y composiciones para el tratamiento de enfermedades por almacenamiento lisosomal |
| EP2684892A1 (en) * | 2012-07-13 | 2014-01-15 | Association Française contre les Myopathies | Compositions and methods for duchenne muscular dystrophy gene therapy |
| EP3763810A3 (en) * | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| KR102315098B1 (ko) | 2012-11-01 | 2021-10-21 | 팩터 바이오사이언스 인크. | 세포에서 단백질을 발현시키는 방법들과 생성물들 |
| WO2014081855A1 (en) * | 2012-11-20 | 2014-05-30 | Universite De Montreal | Methods and compositions for muscular dystrophies |
| JP2016500254A (ja) * | 2012-12-05 | 2016-01-12 | サンガモ バイオサイエンシーズ， インコーポレイテッド | 代謝疾患の調節のための方法および組成物 |
| HUE056638T2 (hu) | 2013-02-22 | 2022-02-28 | Univ Leland Stanford Junior | Telomer kiterjesztéssel kapcsolatos gyógyászati alkalmazás |
| US10704060B2 (en) * | 2013-06-05 | 2020-07-07 | Duke University | RNA-guided gene editing and gene regulation |
| CN104878020B (zh) | 2015-04-29 | 2017-09-15 | 华中农业大学 | 一种控制水稻叶片直立性发育的基因及其应用 |
| AU2017312113B2 (en) * | 2016-08-17 | 2023-05-25 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
-
2013
- 2013-11-01 KR KR1020207015879A patent/KR102315098B1/ko active Active
- 2013-11-01 CA CA3150985A patent/CA3150985A1/en active Pending
- 2013-11-01 EP EP13850281.0A patent/EP2914728B1/en active Active
- 2013-11-01 EP EP20184168.1A patent/EP3786298A1/en not_active Withdrawn
- 2013-11-01 KR KR1020157013918A patent/KR102121086B1/ko active Active
- 2013-11-01 CN CN201380056620.0A patent/CN104769112A/zh active Pending
- 2013-11-01 MX MX2015005346A patent/MX363017B/es unknown
- 2013-11-01 JP JP2015540833A patent/JP6510416B2/ja active Active
- 2013-11-01 BR BR122019025681-0A patent/BR122019025681B1/pt active IP Right Grant
- 2013-11-01 KR KR1020237036946A patent/KR20230154283A/ko not_active Ceased
- 2013-11-01 KR KR1020217033133A patent/KR102596302B1/ko active Active
- 2013-11-01 WO PCT/US2013/068118 patent/WO2014071219A1/en not_active Ceased
- 2013-11-01 BR BR122019025678-0A patent/BR122019025678B1/pt active IP Right Grant
- 2013-11-01 CA CA2890110A patent/CA2890110C/en active Active
- 2013-11-01 RU RU2019143431A patent/RU2019143431A/ru unknown
- 2013-11-01 RU RU2015120524A patent/RU2711249C2/ru active
- 2013-11-01 AU AU2013337651A patent/AU2013337651B2/en active Active
-
2015
- 2015-04-27 MX MX2019002498A patent/MX2019002498A/es unknown
- 2015-04-30 US US14/701,199 patent/US9447395B2/en active Active
- 2015-06-10 US US14/735,603 patent/US9376669B2/en active Active
-
2016
- 2016-05-17 US US15/156,829 patent/US9487768B2/en active Active
- 2016-05-17 US US15/156,806 patent/US9464285B2/en active Active
- 2016-09-20 US US15/270,469 patent/US9657282B2/en active Active
-
2017
- 2017-04-13 US US15/487,088 patent/US9758797B2/en active Active
- 2017-08-07 US US15/670,639 patent/US10415060B2/en active Active
-
2018
- 2018-04-06 JP JP2018073677A patent/JP6793146B2/ja active Active
- 2018-04-06 JP JP2018073676A patent/JP6890565B2/ja active Active
- 2018-11-16 AU AU2018264115A patent/AU2018264115B2/en active Active
-
2019
- 2019-07-26 US US16/523,558 patent/US10590437B2/en active Active
- 2019-10-16 US US16/654,726 patent/US11339410B2/en active Active
- 2019-10-16 US US16/654,536 patent/US10752917B2/en active Active
- 2019-10-16 US US16/654,532 patent/US11339409B2/en active Active
- 2019-10-17 US US16/655,766 patent/US10767195B2/en active Active
- 2019-10-17 US US16/655,760 patent/US11332758B2/en active Active
- 2019-10-17 US US16/655,744 patent/US10724053B2/en active Active
- 2019-10-18 US US16/657,321 patent/US10752918B2/en active Active
- 2019-10-18 US US16/657,318 patent/US11332759B2/en active Active
- 2019-10-18 US US16/657,325 patent/US10752919B2/en active Active
-
2020
- 2020-06-25 US US16/912,321 patent/US12006508B2/en active Active
-
2021
- 2021-02-24 JP JP2021027831A patent/JP7436406B2/ja active Active
- 2021-10-15 AU AU2021250972A patent/AU2021250972A1/en not_active Abandoned
-
2022
- 2022-04-12 US US17/718,668 patent/US20220243228A1/en active Pending
-
2024
- 2024-02-08 JP JP2024018042A patent/JP2024056815A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015534817A5 (OSRAM) | ||
| JP2024001075A5 (OSRAM) | ||
| JP2020510439A5 (OSRAM) | ||
| JP2019524149A5 (OSRAM) | ||
| JP2018534950A5 (OSRAM) | ||
| JP2020524998A5 (OSRAM) | ||
| JP2020511970A5 (OSRAM) | ||
| AU2016341919A1 (en) | CRISPR/CAS-related methods and compositions for treating hepatitis b virus | |
| JP2019508051A5 (OSRAM) | ||
| CA2981508A1 (en) | Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy | |
| EP3589751A1 (en) | RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES | |
| JP2019516680A5 (OSRAM) | ||
| JP2015513897A5 (OSRAM) | ||
| IL310721B1 (en) | Nucleobase editors and their uses | |
| CN108350454A (zh) | 等位基因选择性基因编辑及其用途 | |
| CN108603192A (zh) | 用于调节潜伏的病毒转录的组合物和方法 | |
| JP2018520997A5 (OSRAM) | ||
| JP2013510561A5 (OSRAM) | ||
| JP2015517803A5 (OSRAM) | ||
| RU2022103641A (ru) | Искусственная модификация генома для регуляции экспрессии гена | |
| Gokcumen et al. | Refinement of primate copy number variation hotspots identifies candidate genomic regions evolving under positive selection | |
| JP2017510293A5 (OSRAM) | ||
| US20190024090A1 (en) | Construct for epigenetic modification and its use in the silencing of genes | |
| RU2013122109A (ru) | МОДИФИЦИРОВАННАЯ МОЛЕКУЛА U1мяРНК ЧЕЛОВЕКА, ГЕН, КОДИРУЮЩИЙ МОДИФИЦИРОВАННУЮ МОЛЕКУЛУ U1мяРНК ЧЕЛОВЕКА, ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ГЕН, И ИХ ПРИМЕНЕНИЕ В ГЕННОЙ ТЕРАПИИ | |
| CN118043457A (zh) | 用于插入和编辑大核酸片段的系统和方法 |